Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC By Ogkologos - July 14, 2026 61 0 Facebook Twitter Google+ Pinterest WhatsApp Findings after 7 years of follow-up in the CROWN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength Could Functional Precision Medicine Be the New Precision Oncology? Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL MOST POPULAR Speaking with One Cancer Voice for cancer patients in England March 29, 2023 Associations Between Genomic Features and Response to Neoadjuvant Treatment in a... August 30, 2022 FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and... September 25, 2025 It’s a fair COP: Why our chief clinician went to a... December 13, 2021 Load more HOT NEWS Accepting Help During Cancer Is Hard, But It Can Benefit You... Zanubrutinib’s Approval Improves Targeted Treatment for CLL Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... Genetic Counseling for Hereditary Breast Cancer: What People With a Family...
